O
NVRO

OrbiMed’s NEVRO CORP. NVRO Stock Holding History

OrbiMed’s Portfolio NVRO Stock Details NVRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,357,691
Closed -$77.4M – 155
2018
Q3 		$77.4M Buy
1,357,691
+97,600
+8% +$6.1M 0.93% 28
2018
Q2 		$101M Hold
1,260,091
– – 1.2% 28
2018
Q1 		$109M Buy
1,260,091
+362,300
+40% +$29.3M 1.35% 21
2017
Q4 		$62M Buy
897,791
+402,891
+81% +$32.2M 0.78% 41
2017
Q3 		$45M Buy
494,900
+43,600
+10% +$3.73M 0.43% 64
2017
Q2 		$33.6M Buy
451,300
+373,500
+480% +$29.9M 0.35% 70
2017
Q1 		$7.29M Buy
+77,800
New +$7.05M 0.08% 106

Other funds holding NVRO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

OrbiMed's NVRO Position: Q4 2018 in Review

OrbiMed sold out of NEVRO CORP. (NVRO) in Q4 2018, closing a stake of 1,357,691 shares — an estimated $77.4M sold.

OrbiMed first reported a position in NVRO in Q1 2017 and held it in 7 quarters. The position peaked at $109M in Q1 2018. 157 funds tracked by Wall St. Rank hold NVRO as of Q4 2018.

  • OrbiMed reported no remaining NEVRO CORP. position as of Q4 2018 after selling out during the quarter.
  • OrbiMed sold 1,357,691 NEVRO CORP. shares in Q4 2018, an estimated $77.4M.
  • OrbiMed first reported a position in NEVRO CORP. in Q1 2017 and held it in 7 quarters.
  • OrbiMed's NEVRO CORP. position peaked at $109M in Q1 2018.
  • 157 funds tracked by Wall St. Rank held NEVRO CORP. as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.